#IMRX hashtag - Bluesky

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall

2 months ago

#IMRX Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

www.stocktitan.net/news/IMRX/immuneering-an...

0 0 0 0

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 Immuneering (Nasdaq: IMRX) will host a conference call and live webcast on January 7, 2026 at 4:00 p.m. ET to present updated 12-month overall survival (OS) results from its ongoing Phase 2a trial testing atebimetinib + modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.The company said the webcast will be archived in its Investor Relations Events & Presentations section. Management highlighted confidence in atebimetinib’s potential to extend and improve patient survival and plans to discuss the 12-month OS update during the presentation.

3 months ago

#IMRX Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

www.stocktitan.net/news/IMRX/immuneering-to...

0 0 0 0

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA Immuneering (Nasdaq: IMRX) said it completed End-of-Phase 2 interactions with the FDA and received scientific advice from the EMA, achieving alignment on its planned global Phase 3 registrational trial MAPKeeper 301 for atebimetinib (320 mg QD) + mGnP in first-line metastatic pancreatic ductal adenocarcinoma.The company plans to enroll ~510 patients, use overall survival as the primary endpoint, expects to dose the first patient in mid-2026, and plans to report topline results in mid-2028. Management reiterated that current cash and equivalents are expected to fund operations into 2029. An overall survival update from the Phase 2a trial is planned in the coming weeks.

3 months ago

#IMRX Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

www.stocktitan.net/news/IMRX/immuneering-ad...

0 0 0 0

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) Immuneering (Nasdaq: IMRX) announced it is expected to be added to the Nasdaq Biotechnology Index (NBI). The addition is scheduled to become effective prior to market open on Monday, December 22, 2025.The NBI tracks securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and is evaluated annually each December. Index membership requires meeting eligibility criteria such as minimum market capitalization, average daily trading volume, and public company seasoning. The NBI is calculated using a modified capitalization-weighted methodology.

3 months ago

#IMRX Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

www.stocktitan.net/news/IMRX/immuneering-to...

0 0 0 0

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates Immuneering (NASDAQ: IMRX) reported Q3 2025 results and clinical updates on November 12, 2025. Key clinical news: an 86% overall survival at 9 months in 34 first-line pancreatic cancer patients treated with atebimetinib + mGnP (median follow-up 9 months), favorable tolerability with Grade 3 neutropenia and anemia as the only categories >10%, and new case studies including a complete response and a patient converted to surgery with curative intent after atebimetinib + FOLFIRINOX.Corporate and financial highlights: raised approximately $225 million in financings (including a $25M private placement with Sanofi), cash of $227.6M at Sept 30, 2025 with runway into 2029, and a U.S. composition-of-matter patent for atebimetinib expected to expire in Aug 2042.

4 months ago

#IMRX Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

www.stocktitan.net/news/IMRX/immuneering-re...

0 0 0 0

Most Searched, Thursday November 6, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Thu Nov 6th - #RELY #JBLU #SLDP #ACVA #EOSE #RXRX #BTBT #NUAI #FTEL #NVTS #BITF #STGW #ONDS #DNN #PLUG #USAR #UAMY #INDP #IMRX #AREC - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Sanzhi Kobzhan

@stocks2buy.net

6 months ago

Immuneering Corporation (NASDAQ:IMRX) Price Target and Financial Developments

#stockMarket #investing #IMRX 📈📉 www.stocks2buynow.com/newsitems/im...

0 0 0 0

Most Searched, Thursday September 25, 2025 – Crystal Equity Research

6 months ago

Most searched small-cap stocks, Thu Sept 25th - #EOSE #BTBT #LAES #HTXZ #RR #BB #RXRX #HIVE #ONDS #BITF #EVAX #SPRC #DNN #PLUG #PEPG #SBET #QUBT #LAC #IMRX #AEO - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to

6 months ago

#IMRX Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

www.stocktitan.net/news/IMRX/immuneering-an...

0 0 0 0

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 Immuneering (NASDAQ:IMRX) announced plans to release updated overall survival data from its Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients on September 25, 2025. The trial data, with 9 months median follow-up, follows previously reported exceptional 94% overall survival at 6 months, significantly outperforming the standard of care's 67% survival rate.The company will present the data through an investor call and webcast, followed by a presentation at the PanCAN Scientific Summit on September 28. Additionally, Immuneering will present preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit on September 17.

6 months ago

#IMRX Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

www.stocktitan.net/news/IMRX/immuneering-to...

0 0 0 0

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib Immuneering (Nasdaq: IMRX) has entered into a clinical supply agreement with Eli Lilly to evaluate its lead product candidate atebimetinib in combination with Lilly's olomorasib in a planned Phase 2 trial. The study will focus on patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy.This marks Immuneering's second major collaboration in 2025, following a February agreement with Regeneron to evaluate atebimetinib with Libtayo®. Preclinical studies of the atebimetinib-olomorasib combination have shown promising results, including enhanced tumor regression and delayed resistance. Immuneering will retain global development and commercialization rights to atebimetinib.

7 months ago

#IMRX Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

www.stocktitan.net/news/IMRX/immuneering-an...

0 0 0 0

Leading Indicators, Thursday August 21, 2025 – Crystal Equity Research

7 months ago

Small-cap stocks with improving money flow, Thu Aug 21st - #ZYME #TRST #SENEA #PHVS #MRCC #IMRX #HOPE #VALN #EDUC #CRON #SVV #HRTG #FFWM #CATO - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

94% 6-Month Survival Rate: Immuneering's Pancreatic Cancer Drug Attracts $25M Investment at Premium Biotech firm Immuneering raises $25M through private placement at $3.95/share, following 94% 6-month survival rate in pancreatic cancer trial vs. 67% standard care. Funds to advance atebimetinib development.

7 months ago

#IMRX Immuneering Announces $25 Million Private Placement

www.stocktitan.net/news/IMRX/immuneering-an...

0 0 0 0

Breakthrough in Pancreatic Cancer: New Drug Achieves 94% Survival Rate vs Standard Care's 67% Phase 2a trial reveals exceptional 94% 6-month survival rate for atebimetinib combination therapy in pancreatic cancer, surpassing standard care by 27%. Patent secured until 2042. Learn more.

7 months ago

#IMRX Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/IMRX/immuneering-re...

0 0 0 0

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib Immuneering (Nasdaq: IMRX) has secured a crucial U.S. composition of matter patent for atebimetinib, its innovative cancer drug candidate. The patent, expected to provide exclusivity until August 2042, covers this first-in-class deep cyclic MEK inhibitor designed as a once-daily pill to combat cancer drug resistance.Clinical data has shown remarkable results, with 94% probability of 6-month survival in first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy, compared to 67% with standard care. The drug has received FDA Fast Track designations for first- and second-line pancreatic cancer treatment and NRAS-mutant melanoma, along with orphan drug designation for pancreatic cancer.

8 months ago

#IMRX Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

www.stocktitan.net/news/IMRX/immuneering-gr...

0 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

JUST IN: ( NASDAQ: #IMRX ) Small Cap Rips On Multiple Bullish Analyst Outlooks

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks with strong volume declines, Tue Jun 17th - #YQ #SEDG #RUN #IMRX #FGEN #BNTC #ALDF #VNCE #RDW #LTM #FVR #CTRI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients - 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff,

9 months ago

#IMRX Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

www.stocktitan.net/news/IMRX/immuneering-re...

0 0 0 0

Critical Phase 2a Data Coming: Immuneering's New Pancreatic Cancer Drug Could Change First-Line Treatment Immuneering reveals Phase 2a trial data for IMM-1-104 in first-line pancreatic cancer treatment. Join tomorrow's conference call to see potential breakthrough results.

9 months ago

#IMRX Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

www.stocktitan.net/news/IMRX/immuneering-to...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks overbought with declining relative strength, Thu Jun 12th- #CTEV #KAR #LVWR #AUTL #CTRN #ENTA #IMRX #LOOP #TDUP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 1 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

10 months ago

Small-cap stocks with improving money flow, Mon Jun 2nd - #RMR #NKTR #LOGC #IMRX #HEPS #FTCI #DHAI #CLNN #BYRN #ACIC #XXII #AGM #CLBR #DOLE #ECC #FSLY #GUT #LSPD #OWLT #PINE #YALA #TRML - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

10 months ago

Small-cap stocks with bullish moving average convergence divergence crossovers, Tue May 13th - #YMAB #AMBR #CDNA #IMRX #MERC #NWPX #OXSQ #PHAT #TIPT #XBIT #USAC #RYI #PSTL #PKST #OLP #NINE #HBB #FUBO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates Immuneering (NASDAQ: IMRX) reported its Q1 2025 financial results and provided significant clinical updates. The company highlighted impressive results for IMM-1-104 in pancreatic cancer treatment, including a third-line monotherapy patient with over 13 months progression-free survival and a first-line combination therapy patient achieving complete response. The company's financial position shows $35.9 million in cash as of March 31, 2025, with runway extended into 2026. Q1 net loss was $15.0 million ($0.42 per share). Key developments include appointing Dr. Igor Matushansky as CMO and establishing a clinical trial agreement with Regeneron to evaluate IMM-1-104 with Libtayo in non-small cell lung cancer. The company plans to announce progression-free survival data from over 30 first-line pancreatic cancer patients in Q2'25 and initiate a Phase 3 trial in 2026.

11 months ago

#IMRX Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/IMRX/immuneering-re...

0 0 0 0

Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant Dr. Igor Matushansky joins Immuneering as CMO with 118,000-share option grant at $1.80/share. Strategic appointment bolsters biotech firm's clinical development leadership.

1 year ago

#IMRX Immuneering Corporation Announces Grant of Inducement Award

www.stocktitan.net/news/IMRX/immuneering-co...

1 1 0 0